Currently, there are 863.67M common shares owned by the public and among those 711.62M shares have been available to trade.
The company’s stock has a 5-day price change of -11.80% and -21.15% over the past three months. WBA shares are trading -26.73% year to date (YTD), with the 12-month market performance down to -46.64% lower. It has a 12-month low price of $18.49 and touched a high of $36.58 over the same period. WBA has an average intraday trading volume of 13.82 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -6.88%, -10.80%, and -20.09% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Walgreens Boots Alliance Inc (NASDAQ: WBA) shares accounts for 59.58% of the company’s 863.67M shares outstanding.
It has a market capitalization of $16.50B and a beta (3y monthly) value of 0.77. The earnings-per-share (ttm) stands at -$7.00. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.32% over the week and 3.36% over the month.
Analysts forecast that Walgreens Boots Alliance Inc (WBA) will achieve an EPS of $0.73 for the current quarter, $0.7 for the next quarter and $3.17 for 2025. The lowest estimate earnings-per-share for the quarter is $0.63 while analysts give the company a high EPS estimate of $1. Comparatively, EPS for the current quarter was $1 a year ago. Earnings per share for the fiscal year are expected to decrease by -18.56%, and 0.36% over the next financial year.
Looking at the support for the WBA, a number of firms have released research notes about the stock. Leerink Partners stated their Market Perform rating for the stock in a research note on February 26, 2024, with the firm’s price target at $23. Barclays was of a view on January 03, 2024 that the stock is Underweight, while HSBC Securities gave the stock Hold rating on December 22, 2023, issuing a price target of $27. JP Morgan on their part issued Overweight rating on October 23, 2023.
